SCHEMBL161006

SCHEMBL161006

Nc1cccc(Cc2nn(-c3ccc(F)c(F)c3)ccc2=S)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2D6 P10635 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
SIGMAR1 Q99720 2/20 0.31
MAOA P21397 2/20 0.31
MAOB P27338 2/20 0.31
RXRA P19793 1/20 0.31
GRIN1 Q05586 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041958 0.89 PARP1 (0.33) PARP1CYP11B1CYP11B2MAOAMAOB
SCHEMBL13275009 0.86 PARP1 (0.37) PARP1CYP11B1CYP11B2ALDH1A1HPGD
SCHEMBL255634 0.80 GRM5 (0.46) CYP11B1CYP11B2CYP19A1
SCHEMBL162296 0.78 PARP1 (0.46) PARP1NPSR1FAAHMGLL
SCHEMBL255608 0.77 ALK (0.36) PARP1CYP11B1CYP11B2SIGMAR1
SCHEMBL13275429 0.75 PARP1 (0.38) PARP1CYP11B1CYP11B2ALDH1A1MGLL
SCHEMBL15022584 0.73 F10 (0.34) PARP1
SCHEMBL255722 0.73 PARP1 (0.41) PARP1CYP11B1CYP11B2ALDH1A1MGLL
SCHEMBL13275315 0.71 PARP1 (0.39) PARP1CYP11B1CYP11B2ALDH1A1MGLL
SCHEMBL256018 0.71 TP53 (0.35) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158041-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2013-06-20 US claimed
EP-2611450-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-07-10 EP disclosed
US-20130158041-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2013-06-20 US disclosed
WO-2012030633-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158041-A1 Tyrosine Kinase Inhibitors MET, ABL1, ERBB2 PARP1 2443/4885CYP11B1 2751/4885CYP11B2 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.